

FORWARDHEALTH
PRIOR AUTHORIZATION DRUG ATTACHMENT FOR HEPATITIS C AGENTS

Instructions: Type or print clearly. Before completing this form, read the Prior Authorization Drug Attachment for Hepatitis C Agents Completion Instructions, F-01247A. Providers may refer to the Forms page of the ForwardHealth Portal at www.forwardhealth.wi.gov/WIPortal/Content/provider/forms/index.htm.spage for the completion instructions.

Pharmacy providers are required to have a completed Prior Authorization Drug Attachment for Hepatitis C Agents form signed by the prescriber before submitting a prior authorization (PA) request on the Portal, by fax, or by mail. Providers may call Provider Services at (800) 947-9627 with questions.

SECTION I — MEMBER INFORMATION

1. Name — Member (Last, First, Middle Initial)

2. Member Identification Number

3. Date of Birth — Member

SECTION II — PRESCRIPTION INFORMATION

4. Date Prescription Written

5. Directions for Use

6. Refills

7. Name — Prescriber

8. National Provider Identifier — Prescriber

9. Address — Prescriber (Street, City, State, ZIP+4 Code)

10. Telephone Number — Prescriber

SECTION III — CLINICAL INFORMATION

Note: A copy of the current medical records needs to be submitted with the PA request, including the following:

- Hepatitis C virus (HCV) assessment and treatment plan, including psychosocial history.
- Assessment of other significant or uncontrolled diseases, including complete problem list.
- Complete medication list.
- Lab data: Liver function tests, complete blood count, serum creatinine, albumin, international normalized ratio.

11. Diagnosis Code and Description

12. Date Member Was Diagnosed with Hepatitis C

13. Indicate the likely source of the HCV infection.

14. Indicate the member's HCV genotype and subtype.

15. Is the member 18 years of age or older?

Yes No

16. Is the member pregnant?

Yes No

17. Has the member had a liver transplant?

Yes No

18. Is the member on a liver transplant wait list?

Yes No

Continued



SECTION III — CLINICAL INFORMATION (Continued)

19. Does the member have hepatocellular carcinoma? Yes No

20. Indicate the member's most recent hepatitis C virus ribonucleic acid (HCV-RNA) level and the date it was taken.

HCV-RNA _____ IU / mL Test Date _____

21. Indicate the member's proposed hepatitis C drug treatment regimen.

Drug Name _____ Daily Dose _____ Expected Duration _____

Currently taking? Yes No If yes, enter the date started. _____

Drug Name _____ Daily Dose _____ Expected Duration _____

Currently taking? Yes No If yes, enter the date started. _____

Drug Name _____ Daily Dose _____ Expected Duration _____

Currently taking? Yes No If yes, enter the date started. _____

22. Indicate the member's previous hepatitis C drug therapy or check "hepatitis c treatment naïve" if appropriate.

Hepatitis C Treatment Naïve

Drug Name _____ Daily Dose _____ Dates Taken _____

Drug Name _____ Daily Dose _____ Dates Taken _____

Drug Name _____ Daily Dose _____ Dates Taken _____

Drug Name _____ Daily Dose _____ Dates Taken _____

23. List all non-hepatitis C drugs the member is currently receiving or check "none" if appropriate.

None

Drug Name _____ Drug Name _____ Drug Name _____

Drug Name _____ Drug Name _____ Drug Name _____

Drug Name _____ Drug Name _____ Drug Name _____

Drug Name _____ Drug Name _____ Drug Name _____

24. Does the member have a history of alcohol abuse or illicit drug use? Yes No

If yes, provide details.

25. If the member has a history of alcohol abuse or illicit drug use, when did he or she last participate in alcohol abuse or illicit drug use? Provide documentation of at least six months of abstinence from alcohol abuse or illicit drug use.

26. If the member has a history of alcohol abuse or illicit drug use, is he or she currently participating in a recovery program, including counseling services, addiction specialist, and toxicology screening? Yes No

If yes, provide details.

SECTION III — CLINICAL INFORMATION (Continued)

27. Has the member had a liver biopsy? Yes No

If yes, provide the date taken. _____

Note: A copy of the results must be submitted with the PA request.

28. Has the member had a liver ultrasound or scan? Yes No

If yes, provide the date taken. _____

Note: A copy of the results must be submitted with the PA request.

29. If a Metavir score was calculated, provide the score, or write "None" if appropriate. (Scoring: 0 = No scarring; 1 = Minimal scarring; 2 = Scarring has occurred and extends outside the areas in the liver that contain blood vessels; 3 = Bridging fibrosis is spreading and connecting to other areas that contain fibrosis; 4 = Cirrhosis or advanced scarring of the liver.)

30. Does the member have cirrhosis of the liver? Yes No

If yes, is the cirrhosis compensated? Yes No

If yes, what was the member's most recent Child-Turcotte-Pugh Score? _____

Note: A copy of the clinical documentation that indicates the member is compensated, including physical exam findings, must be submitted with the PA request.

31. Is the member coinfecting with hepatitis A, hepatitis B, or Human Immunodeficiency Virus? Yes No

If yes, list the coinfection(s).

32. Is the member a candidate for treatment with interferon alfa? Yes No

If no, explain why the member is unable to take interferon alfa.

Note: If mental health conditions are the basis for the member being unable to take interferon alfa, documentation from the member's mental health provider must be submitted with the PA request.

33. Is the member a candidate for treatment with ribavirin? Yes No

If no, explain why the member is unable to take ribavirin.

SECTION IV — AUTHORIZED SIGNATURE

34. SIGNATURE — Prescriber

35. Date Signed

SECTION V — ADDITIONAL INFORMATION

36. Include any additional information in the space below. Additional diagnostic and clinical information explaining the need for the drug requested may also be included here.
